Olink Holding AB (publ)
OLK
Rank in Stocks
#4794
Olink Holding AB (publ) offers a comprehensive suite of products and services... Olink Holding AB (publ) offers a comprehensive suite of products and services tailored for life science research institutions, including academic bodies, government entities, biopharmaceutical companies, and biotechnology firms. The company's product lines include Olink Explore, which is designed to aid research in critical areas such as cardiovascular and metabolic health, oncology, neurology, and inflammation. Additionally, it features the Olink Target product line and the Olink Focus product line, the latter providing bespoke solutions for clients who have already pinpointed specific proteins or protein signatures for their studies. Beyond these, Olink supplies the Signature Q100, a dedicated platform for qPCR (quantitative Polymerase Chain Reaction) readouts. Its service portfolio encompasses Olink Analysis, offering end-to-end support from study design and expert consultation to sample preparation, assay execution, and stringent quality control of data, complemented by bioinformatics services. For data management and analysis, Olink provides the normalized protein expression (NPX) Manager, a specialized software tool enabling users to import data, validate its quality, and normalize findings in preparation for statistical analysis. Furthermore, Olink Insight serves as a cloud-based platform for visualizing and statistically analyzing NPX data. Olink Holding AB (publ) markets and sells its offerings worldwide through its proprietary direct sales force, reaching customers across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Established in 2004 and based in Uppsala, Sweden, the company underwent a name change in January 2021 from its former identity, Knilo HoldCo AB, to its current designation. It operates as a subsidiary of Summa Equity Holding AB.
Share Price
$26.08
Last synced: 2024-07-09
Market Cap
$3.10B
Change (1 day)
0.31%
Change (1 year)
0.00%
Country
SE
Trade Olink Holding AB (publ) (OLK)
Category
Healthcare
P/E ratio for Olink Holding AB (publ) (OLK)
P/E ratio as of October 2026 TTM: -100.31
According to Olink Holding AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -100.31. At the end of 2022 the company had a P/E ratio of -235.17.
P/E ratio history for Olink Holding AB (publ) from 2019 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -100.31 | 1.82% |
| 2023 | -98.51 | -58.11% |
| 2022 | -235.17 | 399.08% |
| 2021 | -47.12 | -92.54% |
| 2020 | -631.90 | 163.69% |
| 2019 | -239.64 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 36.15 | -136.04% |
US
|
|
| 39.77 | -139.65% |
US
|
|
| -290.26 | 189.37% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -134.08% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.